伊布替尼联合FCR一线治疗年轻CLL的单臂多中心2期试验
该单臂多中心2期试验在≤65岁初治CLL患者中评估伊布替尼联合FCR的限时方案。研究者认为该方案在预后标志物不限人群中MRD阴性率系已发表最高,作为限时一线方案具有前景。
要点
- 伊布替尼联合FCR后28/85例(33%)达CR且骨髓MRD阴性,优于FCR历史值20%。
- 最常见全等级毒性为血液学:血小板减少74%、中性粒细胞减少62%、贫血49%。
核心结论
- 伊布替尼联合FCR在≤65岁初治CLL中骨髓MRD阴性率为已发表最高(预后标志物不限人群),作为限时一线方案具有前景。
研究设计与样本
- 多中心、开放标签、非随机、单臂2期试验,美国7个中心,入组≤65岁初治CLL患者85例。
- 初始队列不限预后标志物(含del(17p)或TP53异常),方案修订后扩展队列排除del(17p)。
- 伊布替尼420mg/日口服7天后联合最多6周期FCR(氟达拉滨25mg/m2 d1-3,环磷酰胺250mg/m2 d1-3,利妥昔单抗第1周期375mg/m2 d1、第2-6周期500mg/m2 d1),持续口服伊布替尼420mg/日;缓解者伊布替尼维持至2年,2年后骨髓MRD阴性者可停药。
- 主要终点为末次伊布替尼联合FCR后2个月骨髓MRD阴性的完全缓解比例,按方案分析所有至少接受一剂治疗者。
主要发现
- 2014年10月23日至2018年4月23日入组85例,中位年龄55岁(IQR 50-58);del(17p) 4/83例(5%),TP53突变3/81例(4%),2例同时具有两者。
- 研究期间最佳骨髓MRD阴性71/85例(84%)。
- 1例疾病进展,1例死亡(伊布替尼维持17个月后心脏性猝死,评估可能与伊布替尼相关)。
- 最常见全等级毒性为血液学:血小板减少63例(74%)、中性粒细胞减少53例(62%)、贫血41例(49%);3/4级非血液学严重不良事件包括3级房颤3例(4%)、3级耶氏肺孢子菌肺炎2例(2%)。
关键数值与推荐
- 伊布替尼口服420mg/日先用7天,后续联合FCR时持续口服420mg/日。
- 氟达拉滨25mg/m2静脉d1-3,环磷酰胺250mg/m2静脉d1-3,利妥昔单抗第1周期375mg/m2 d1、第2-6周期500mg/m2 d1,每28天为一周期,最多6周期。
- 缓解者伊布替尼维持至2年;2年后骨髓MRD阴性者可停药。
临床怎么用
- 对于≤65岁初治fit CLL患者,可考虑伊布替尼联合FCR的限时方案,2年后骨髓MRD阴性者可停药。
- 治疗期间需监测血液学毒性(血小板减少、中性粒细胞减少、贫血)及非血液学严重不良事件(房颤、耶氏肺孢子菌肺炎)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fludarabine, cyclophosphamide, and rituximab (FCR) can improve disease-free survival for younger (age ≤65 years) fit patients with chronic lymphocytic leukaemia with mutated IGHV. However, patients with unmutated IGHV rarely have durable responses. Ibrutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation status but requires continuous treatment. We postulated that time-limited ibrutinib plus FCR would induce durable responses in younger fit patients with chronic lymphocytic leukaemia. METHODS: We did a multicentre, open-label, non-randomised, single-arm phase 2 trial at seven sites in the USA. We enrolled patients aged 65 years or younger with previously untreated chronic lymphocytic leukaemia. Our initial cohort (original cohort) was not restricted by prognostic marker status and included patients who had del(17p) or TP53 aberrations. After a protocol amendment (on March 21, 2017), we enrolled an additional cohort (expansion cohort) that included patients without del(17p). Ibrutinib was given orally (420 mg/day) for 7 days, then up to six 28-day cycles were administered intravenously of fludarabine (25 mg/m2, days 1-3), cyclophosphamide (250 mg/m2, days 1-3), and rituximab (375 mg/m2 day 1 of cycle 1; 500 mg/m2 day 1 of cycles 2-6) with continuous oral ibrutinib (420 mg/day). Responders continued on ibrutinib maintenance for up to 2 years, and patients with undetectable minimal residual disease in bone marrow after 2 years were able to discontinue treatment. The primary endpoint was the proportion of patients who achieved a complete response with undetectable minimal residual disease in bone marrow 2 months after the last cycle of ibrutinib plus FCR. Analyses were done per-protocol in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov (NCT02251548) and is ongoing. FINDINGS: Between Oct 23, 2014, and April 23, 2018, 85 patients with chronic lymphocytic leukaemia were enrolled. del(17p) was detected in four (5%) of 83 patients and TP53 mutations were noted in three (4%) of 81 patients; two patients had both del(17p) and TP53 mutations. Median patients' age was 55 years (IQR 50-58). At data cutoff, median follow-up was 16·5 months (IQR 10·6-34·1). A complete response and undetectable minimal residual disease in bone marrow 2 months after the last cycle of ibrutinib plus FCR was achieved by 28 (33%, 95% CI 0·23-0·44) of 85 patients (p=0·0035 compared with a 20% historical value with FCR alone). A best response of undetectable minimal residual disease in bone marrow was achieved by 71 (84%) of 85 patients during the study. One patient had disease progression and one patient died (sudden cardiac death after 17 months of ibrutinib maintenance, assessed as possibly related to ibrutinib). The most common all-grade toxic effects were haematological, including thrombocytopenia in 63 (74%) patients, neutropenia in 53 (62%), and anaemia in 41 (49%). Grade 3 or 4 non-haematological serious adverse events included grade 3 atrial fibrillation in three (4%) patients and grade 3 Pneumocystis jirovecii pneumonia in two (2%). INTERPRETATION: The proportion of patients who achieved undetectable minimal residual disease in bone marrow with ibrutinib plus FCR is, to our knowledge, the highest ever published in patients with chronic lymphocytic leukaemia unrestricted by prognostic marker status. Ibrutinib plus FCR is promising as a time-limited combination regimen for frontline chronic lymphocytic leukaemia treatment in younger fit patients. FUNDING: Pharmacyclics and the Leukemia & Lymphoma Society.
引用
- Davids MS, Brander DM, Kim HT, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019. PMID: 31208944. doi:10.1016/S2352-3026(19)30104-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。